Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Druckformat: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i1.30
pages 17-30

Therapeutic Targeting of BCR-ABL: Prognostic Markers of Response and Resistance Mechanism in Chronic Myeloid Leukaemia

David T. Yeung
Haematology Department, SA Pathology (RAH Site), Centre for Cancer Biology, and University of Adelaide, Adelaide, Australia.
Timothy P. Hughes
Haematology Department, SA Pathology (RAH Site), Centre for Cancer Biology, and University of Adelaide, Adelaide, Australia

ABSTRAKT

Chronic myeloid leukemia (CML) is caused by the formation of the BCR-ABL fusion protein as a result of the t(9;22) chromosomal translocation. The elucidation of its molecular pathogenesis led to the identification of a therapeutic target and the subsequent synthesis and introduction of a small-molecule inhibitor for this target, imatinib. Because CML is the first disease successfully treated by targeted kinase inhibition, it served as a paradigm for discovery of disease mechanism and drug development in other diseases in which constitutive kinase expression plays a central role in pathogenesis. Despite the spectacular success of imatinib, not all CML patients derive great benefit from it. This review will cover some of the currently known prognostic markers of disease response and potential resistance mechanisms.


Articles with similar content:

FLT3 Signaling and the Development of Inhibitors That Target FLT3 Kinase Activity
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
Wallace Y. Langdon
Natural Products as Inhibitors of Epidermal Growth Factor Receptor
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth
Druggable Targets in Pancreatic Adenocarcinoma
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Cristina Napoli, Stefania Nobili, Ida Landini, Gabriele Perrone, Enrico Mini, Renato Tassi
Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Diego Alvarado, Andrew J. Garton, Theresa M. LaVallee, Gerald McMahon, E. Sergio Trombetta, Richard Gedrich
Raf Kinase Inhibitory Protein (RKIP) as a Metastasis Suppressor: Regulation of Signaling Networks in Cancer
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Marsha Rich Rosner, Ali E. Yesilkanal